These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome. Cossins J; Liu WW; Belaya K; Maxwell S; Oldridge M; Lester T; Robb S; Beeson D Hum Mol Genet; 2012 Sep; 21(17):3765-75. PubMed ID: 22661499 [TBL] [Abstract][Full Text] [Related]
7. Dok-7/MuSK signaling and a congenital myasthenic syndrome. Yamanashi Y; Higuch O; Beeson D Acta Myol; 2008 Jul; 27(1):25-9. PubMed ID: 19108574 [TBL] [Abstract][Full Text] [Related]
8. Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure. Rodríguez Cruz PM; Cossins J; Cheung J; Maxwell S; Jayawant S; Herbst R; Waithe D; Kornev AP; Palace J; Beeson D Hum Mutat; 2020 Mar; 41(3):619-631. PubMed ID: 31765060 [TBL] [Abstract][Full Text] [Related]
9. Arecoline inhibits and destabilizes agrin-induced acetylcholine receptor cluster formation in C2C12 myotubes. Chang YF; Liu TY; Liu ST Food Chem Toxicol; 2013 Oct; 60():391-6. PubMed ID: 23933062 [TBL] [Abstract][Full Text] [Related]
10. [The role of protein tyrosine phosphatases Shp-2 involved in the formation of the neuromuscular junction]. Zhao XT; Zhang Z Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(15):1052-6. PubMed ID: 16784710 [TBL] [Abstract][Full Text] [Related]
12. Congenital myasthenic syndromes and the formation of the neuromuscular junction. Beeson D; Webster R; Cossins J; Lashley D; Spearman H; Maxwell S; Slater CR; Newsom-Davis J; Palace J; Vincent A Ann N Y Acad Sci; 2008; 1132():99-103. PubMed ID: 18567858 [TBL] [Abstract][Full Text] [Related]
13. The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. McMacken G; Cox D; Roos A; Müller J; Whittaker R; Lochmüller H Hum Mol Genet; 2018 May; 27(9):1556-1564. PubMed ID: 29462491 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine phosphatases such as SHP-2 act in a balance with Src-family kinases in stabilization of postsynaptic clusters of acetylcholine receptors. Camilleri AA; Willmann R; Sadasivam G; Lin S; Rüegg MA; Gesemann M; Fuhrer C BMC Neurosci; 2007 Jul; 8():46. PubMed ID: 17605785 [TBL] [Abstract][Full Text] [Related]
15. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. Lorenzoni PJ; Scola RH; Kay CS; Filla L; Miranda AP; Pinheiro JM; Chaouch A; Lochmüller H; Werneck LC J Neurol Sci; 2013 Aug; 331(1-2):155-7. PubMed ID: 23790237 [TBL] [Abstract][Full Text] [Related]
16. Agrin elicits membrane lipid condensation at sites of acetylcholine receptor clusters in C2C12 myotubes. Stetzkowski-Marden F; Gaus K; Recouvreur M; Cartaud A; Cartaud J J Lipid Res; 2006 Oct; 47(10):2121-33. PubMed ID: 16816402 [TBL] [Abstract][Full Text] [Related]
17. Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Cossins J; Burke G; Maxwell S; Spearman H; Man S; Kuks J; Vincent A; Palace J; Fuhrer C; Beeson D Brain; 2006 Oct; 129(Pt 10):2773-83. PubMed ID: 16945936 [TBL] [Abstract][Full Text] [Related]
18. The function of cortactin in the clustering of acetylcholine receptors at the vertebrate neuromuscular junction. Madhavan R; Gong ZL; Ma JJ; Chan AW; Peng HB PLoS One; 2009 Dec; 4(12):e8478. PubMed ID: 20041195 [TBL] [Abstract][Full Text] [Related]
19. Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction. Chen F; Qian L; Yang ZH; Huang Y; Ngo ST; Ruan NJ; Wang J; Schneider C; Noakes PG; Ding YQ; Mei L; Luo ZG Neuron; 2007 Jul; 55(2):247-60. PubMed ID: 17640526 [TBL] [Abstract][Full Text] [Related]
20. Calcitriol ameliorates motor deficits and prolongs survival of Chrne-deficient mouse, a model for congenital myasthenic syndrome, by inducing Rspo2. Ohkawara B; Tomita H; Inoue T; Zhang S; Kanbara S; Koshimizu H; Miyasaka Y; Takeda JI; Nishiwaki H; Nakashima H; Ito M; Masuda A; Ishiguro N; Ogi T; Ohno T; Imagama S; Ohno K Neurotherapeutics; 2024 Mar; 21(2):e00318. PubMed ID: 38233267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]